Analyst Ranking
Top 10%
#473 out of 5184 analysts
Average Return
+31.97%
Win Rate
44%16 out of 36
Risk vs Reward
Poor
Good

Yuan Zhi's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Fusion Pharmaceuticals IncFUSN
+554.97%$3.22$21.09
2023-10-03 -
2024-03-20
Strong Buy
Fusion Pharmaceuticals IncFUSN
+446.37%$3.86$21.09
2023-03-30 -
2024-03-20
Strong Buy
Fusion Pharmaceuticals IncFUSN
+141.92%$2.29$5.54
2022-12-01 -
2023-11-30
Strong Buy
Tango Therapeutics IncTNGX
+134.62%$3.38$7.93
2024-11-11 -
2025-11-10
Strong Buy
Hyperfine IncHYPR
+105.00%$0.60$1.23
2025-05-15 -
2026-01-28
Strong Buy

Yuan Zhi's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Radiopharm Theranostics LtdRADX
3Strong Buy$16.00+218.09%Reiterates
a month ago
Radnet IncRDNT
2Strong Buy$87.00+21.41%Maintains
2 months ago
Tango Therapeutics IncTNGX
3Strong Buy$14.00+25.22%Maintains
2 months ago
Perspective Therapeutics IncCATX
4Strong Buy$11.00+329.69%Maintains
2 months ago
Mirion Technologies IncMIR
3Strong Buy$22.00-13.32%Reiterates
6 months ago
Oncology Institute IncTOI
1Strong Buy$6.00+100.00%Initiates Coverage On
6 months ago
Hyperfine IncHYPR
2Strong Buy$1.00-18.70%Maintains
8 months ago
Agenus IncAGEN
2Strong Buy$18.00N/AMaintains
a year ago
Cryoport IncCYRX
4Strong Buy$15.00N/AUpgrades
a year ago
Cytosorbents CorpCTSO
1Strong Buy$3.00N/AReiterates
2 years ago
Fusion Pharmaceuticals IncFUSN
4Hold$23.00N/ADowngrades
2 years ago
Azenta IncAZTA
3Strong Buy$79.00N/AMaintains
2 years ago
Ambrx Biopharma IncAMAM
2Hold$28.00N/ADowngrades
2 years ago
Actinium Pharmaceuticals IncATNM
4Strong Buy$16.00N/AMaintains
2 years ago
Iveric Bio IncISEE
3Hold$19.00N/AMaintains
3 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.